Quadrant Capital Group LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 23.7% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 16,554 shares of the company’s stock after buying an additional 3,176 shares during the quarter. Johnson & Johnson makes up about 0.8% of Quadrant Capital Group LLC’s investment portfolio, making the stock its 24th largest position. Quadrant Capital Group LLC’s holdings in Johnson & Johnson were worth $2,099,000 as of its most recent filing with the SEC.

Several other hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. lifted its holdings in shares of Johnson & Johnson by 4.7% in the first quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock worth $22,476,102,000 after buying an additional 7,853,141 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Johnson & Johnson by 2.0% in the first quarter. Massachusetts Financial Services Co. MA now owns 29,761,934 shares of the company’s stock worth $3,813,993,000 after buying an additional 590,069 shares in the last quarter. Boston Partners lifted its holdings in shares of Johnson & Johnson by 68.7% in the first quarter. Boston Partners now owns 12,783,909 shares of the company’s stock worth $1,638,258,000 after buying an additional 5,207,124 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in shares of Johnson & Johnson by 2.8% in the fourth quarter. Fisher Asset Management LLC now owns 12,127,379 shares of the company’s stock worth $1,694,437,000 after buying an additional 329,705 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Johnson & Johnson by 4.7% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,590,694 shares of the company’s stock worth $1,100,897,000 after buying an additional 383,040 shares in the last quarter. 66.22% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have recently commented on JNJ. Credit Suisse Group set a $151.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, June 12th. Deutsche Bank reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, April 18th. Jefferies Financial Group set a $145.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, July 15th. Citigroup decreased their price target on shares of Johnson & Johnson from $146.00 to $134.00 and set a “neutral” rating on the stock in a research note on Monday, April 23rd. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $160.00 price target (down previously from $175.00) on shares of Johnson & Johnson in a research note on Wednesday, April 18th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the company. Johnson & Johnson presently has an average rating of “Hold” and an average price target of $142.63.

Johnson & Johnson opened at $131.20 on Friday, Marketbeat Ratings reports. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32. The firm has a market cap of $352.69 billion, a P/E ratio of 16.85, a price-to-earnings-growth ratio of 2.01 and a beta of 0.73. The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The business had revenue of $20.83 billion for the quarter, compared to the consensus estimate of $20.39 billion. During the same quarter in the prior year, the firm posted $1.83 earnings per share. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. equities research analysts predict that Johnson & Johnson will post 8.14 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 11th. Stockholders of record on Tuesday, August 28th will be paid a $0.90 dividend. This represents a $3.60 annualized dividend and a dividend yield of 2.74%. The ex-dividend date is Monday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 49.32%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Price to Earnings Ratio (PE), For Valuing Stocks

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.